CARDISIO

Cardisio GmbH, founded in 2016 and headquartered in Frankfurt am Main, is committed to the early detection of heart disease. Cardisiography (CSG) is a method that quickly, precisely, and non-invasively detects pathological patterns that are indicative of heart disease... In Cardisio's future, everyone has access to a scientifically proven, highly accurate, and non-invasive screening procedure for heart diseases that is easy to use, examiner-independent, and affordable for everyone. We aim to reduce cardiac deaths, complications, and healthcare costs by providing more effective heart exams globally... Cardisiography is a groundbreaking AI-based cardiac screening that can discover heart disease in its earliest stages.

Also known as: Cardisio GmbH, Cardisio USA

Registration numbers: HRB 104584 (W)

VAT numbers: DE308826196

Primary location: Cranfield United Kingdom